Table S1: Cell Line Characterization

Cell Line	Cancer Type	Subtype	Culture Properties	EPCAM expression
MDA-MB-231TD	Breast	Basal B[1]	Adherent	Low[2]
MDA-MB-436	Breast	Basal B[1]	Adherent	Low-Negative[2]
MCF-7	Breast	Luminal[1]	Highly Adherent	High[3]
SNU-C1	Colon	Transit-Amplifying (TA)[4]	Suspended	High[5]
T84	Colon	Transit-Amplifying (TA)[4]	Highly Adherent	High[6]
H1755	Lung	Non-small cell (NSCLC)	Adherent with single cells in suspension	Negative[7]
H1944	Lung	Non-small cell (NSCLC)	Adherent	N/A
H2087	Lung	Non-small cell (NSCLC)	Adherent	N/A
PC-3	Prostate	Androgen Receptor (AR)- [8]	Adherent	Low-Moderate[9]
LNCaP	Prostate	Androgen Receptor (AR)+ [8]	Loosely Adherent	High[9]

References

1 Neve, R. M. *et al.* A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell* **10**, 515-527, doi:10.1016/j.ccr.2006.10.008 (2006).

2 Li, W. M., Zhou, L. L., Zheng, M. & Fang, J. Selection of Metastatic Breast Cancer Cell-Specific Aptamers for the Capture of CTCs with a Metastatic Phenotype by Cell-SELEX. *Mol Ther Nucleic Acids* **12**, 707-717, doi:10.1016/j.omtn.2018.07.008 (2018).

3 Sterzynska, K., Kempisty, B., Zawierucha, P. & Zabel, M. Analysis of the specificity and selectivity of anti-EpCAM antibodies in breast cancer cell lines. *Folia Histochem Cytobiol* **50**, 534-541, doi:10.5603/17845 (2012).

4 Sadanandam, A. *et al.* A colorectal cancer classification system that associates cellular phenotype and responses to therapy. *Nat Med* **19**, 619-625, doi:10.1038/nm.3175 (2013).

5 Park, B. S. *et al.* Comparison of putative circulating cancer stem cell detection between the hepatic portal system and peripheral blood in colorectal cancer patients. *Ann Surg Treat Res* **87**, 232-238, doi:10.4174/astr.2014.87.5.232 (2014).

6 Gelderman, K. A., Kuppen, P. J., Bruin, W., Fleuren, G. J. & Gorter, A. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. *Eur J Immunol* **32**, 128-135, doi:10.1002/1521-4141(200201)32:1<128::AID-IMMU128>3.0.CO;2-P (2002).

7 Watanabe, M. *et al.* A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood. *J Transl Med* **12**, 143, doi:10.1186/1479-5876-12-143 (2014).

8 Tai, S. *et al.* PC3 is a cell line characteristic of prostatic small cell carcinoma. *Prostate* **71**, 1668-1679, doi:10.1002/pros.21383 (2011).

9 Lowes, L. E. *et al.* Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer. *Oncotarget* **7**, 76125-76139, doi:10.18632/oncotarget.12682 (2016).